Elitek Related Clinical Trials
Rasburicase in Patients at Risk for Tumor Lysis Syndrome [Completed]
Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS [Completed]
Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies [Terminated]
Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2 [Recruiting]
Fasturtec TLS Treatment / Prophylysis [Completed]
Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma [Completed]
Rasburicase for Hyperuricemia [Completed]
Rasburicase in Tumor Lysis Syndrome [Completed]
Elitek (Rasburicase) Immuno-Monitoring Study [Terminated]
Lowering Serum Uric Acid to Prevent Acute Kidney Injury [Completed]
Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome [Completed]
Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma [Completed]
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients [Completed]
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant [Completed]
Rasburicase (Fasturtec) Registration Trial [Terminated]
Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma [Terminated]
Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome [Completed]
Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma [Completed]
Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy [Completed]
Effect of Reducing Uric Acid on Insulin Sensitivity and Oxidative Status [Completed]
Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia [Completed]
The Relationship Between Uric Acid and Inflammatory Markers [Completed]
Mature B-Cell Lymphoma And Leukemia Study III [Recruiting]
Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout [Completed]
A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program [Not yet recruiting]
|